换一批Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
第一作者：
Benoit,Cadieux
第一单位：
Amgen Inc., Thousand Oaks, CA, USA.
作者：
关键词
AFF, Atypical femoral fractureBM, Bone metastasisBMFS, BM-free survivalBP, BisphosphonateBTA, Bone-targeting agentBone metastasisCI, Confidence intervalDenosumabEfficacyHR, Hazard ratioHRQoL, Health-related quality of lifeIMWG, International Myeloma Working GroupMM, Multiple myelomaMVF, Multiple vertebral fractureNSCLC, Non–small-cell lung cancerONJ, Osteonecrosis of the jawOPG, OsteoprotegerinOS, Overall survivalPFS, Progression-free survivalQ12W, Every 12 weeksQ4W, Every 4 weeksRANKL, Receptor activator of nuclear factor-κB ligandSC, SubcutaneousSRE, Skeletal-related eventSafetySkeletal-related eventsuNTx/Cr, Urinary N-telopeptide normalized to urinary creatinine
DOI
10.1016/j.jbo.2022.100416
PMID
35242510
发布时间
2022-03-05
- 浏览0
Journal of bone oncology
2022年33卷
100416页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
